Cosmo Bio CoTSE:3386 -0.32%71 Operating Margin % is 1.25% as of Dec. 2025, which is 77% below its 10-year median of 5.46. GuruFocus rates TSE:3386 with a GF Score™ of 71/100 and a GF Value™ of 円1,244.50 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 56.86% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Cosmo Bio Co's Operating Income for the
six
months ended in Dec. 2025 was 円67 Mil. Cosmo Bio Co's Revenue for the
six
months ended in Dec. 2025 was 円5,364 Mil. Therefore, Cosmo Bio Co's Operating Margin % for the quarter that ended in Dec. 2025 was 1.25%.
Warning Sign:
Cosmo Bio Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -24%.
The historical rank and industry rank for Cosmo Bio Co's Operating Margin % or its related term are showing as below:
TSE:3386'
s Operating Margin % Range Over the Past 10 Years
Min: 2.73 Med: 5.46 Max: 11.36
Current: 3.19
TSE:3386's Operating Margin % is ranked better than 56.86% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195
vs TSE:3386: 3.19
Cosmo Bio Co's 5-Year Average Operating Margin % Growth Rate was -24.00% per year.
Cosmo Bio Co (TSE:3386) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cosmo Bio Co Operating Margin % Related Terms
Cosmo Bio Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cosmo Bio Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a Operating Margin % of 1.25% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Cosmo Bio Co and its competitors. This is 77% below median its historical median of 5.46. Over the past decade, Cosmo Bio Co's Operating Margin % has ranged from 2.73 to 11.36. According to the industry distribution chart, Cosmo Bio Co ranks #88 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 43.1%.
Is Cosmo Bio Co's Operating Margin % too high?
Cosmo Bio Co's current Operating Margin % of 1.25% is 77% below median its 10-year median of 5.46. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 11.36. Based on the distribution chart, Cosmo Bio Co ranks #88 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cosmo Bio Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #88 out of 204 companies for Operating Margin %. This puts Cosmo Bio Co in the upper half of its industry. Historically, Cosmo Bio Co's own Operating Margin % has ranged from 2.73 to 11.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cosmo Bio Co and its competitors. Cosmo Bio Co's current Operating Margin % is 1.25%, which is 77% below median its own 10-year median of 5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,244.50, compared to a current price of 円1,235.00 — trading 0.8% below its estimated fair value. The current Operating Margin % is 1.25%, which is 77% below median its 10-year median of 5.46. Cosmo Bio Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current Operating Margin % is 1.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be undervalued.
The current stock price of 円1,235.00 is trading 0.8% below its estimated GF Value™ of 円1,244.50.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
Operating Margin %: 1.25% (77% below median its 10-year median of 5.46)
GF Value™: 円1,244.50 vs. price of 円1,235.00 (0.8% below fair value)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
71GF Score
Get the complete analysis for TSE:3386
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
